1. Home
  2. LQDA vs SONO Comparison

LQDA vs SONO Comparison

Compare LQDA & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • SONO
  • Stock Information
  • Founded
  • LQDA 2004
  • SONO 2002
  • Country
  • LQDA United States
  • SONO United States
  • Employees
  • LQDA N/A
  • SONO N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • SONO Consumer Electronics/Video Chains
  • Sector
  • LQDA Health Care
  • SONO Consumer Discretionary
  • Exchange
  • LQDA Nasdaq
  • SONO Nasdaq
  • Market Cap
  • LQDA 1.4B
  • SONO 1.1B
  • IPO Year
  • LQDA 2018
  • SONO 2018
  • Fundamental
  • Price
  • LQDA $14.92
  • SONO $10.28
  • Analyst Decision
  • LQDA Strong Buy
  • SONO Buy
  • Analyst Count
  • LQDA 8
  • SONO 3
  • Target Price
  • LQDA $27.13
  • SONO $13.00
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • SONO 2.0M
  • Earning Date
  • LQDA 05-08-2025
  • SONO 05-07-2025
  • Dividend Yield
  • LQDA N/A
  • SONO N/A
  • EPS Growth
  • LQDA N/A
  • SONO N/A
  • EPS
  • LQDA N/A
  • SONO N/A
  • Revenue
  • LQDA $14,144,000.00
  • SONO $1,463,138,000.00
  • Revenue This Year
  • LQDA $224.65
  • SONO N/A
  • Revenue Next Year
  • LQDA $250.54
  • SONO $5.15
  • P/E Ratio
  • LQDA N/A
  • SONO N/A
  • Revenue Growth
  • LQDA N/A
  • SONO N/A
  • 52 Week Low
  • LQDA $8.26
  • SONO $7.63
  • 52 Week High
  • LQDA $19.41
  • SONO $16.30
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.94
  • SONO 52.36
  • Support Level
  • LQDA $13.94
  • SONO $9.65
  • Resistance Level
  • LQDA $17.88
  • SONO $10.72
  • Average True Range (ATR)
  • LQDA 1.40
  • SONO 0.32
  • MACD
  • LQDA -0.33
  • SONO -0.01
  • Stochastic Oscillator
  • LQDA 17.92
  • SONO 35.59

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About SONO Sonos Inc.

Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.

Share on Social Networks: